ALU repeat as potential molecular marker in the detection and prognosis of different cancer types: A systematic review
- Authors:
- Semaa A. Shaban
- Aya M. Al‑Rahim
- Ahmed Abduljabbar Suleiman
-
Affiliations: Department of Biology, College of Sciences, Tikrit University, Tikrit, Saladin 34001, Iraq, Department of Molecular and Medical Biotechnology, College of Biotechnology, Al‑Nahrain University, Baghdad 64074, Iraq, Department of Biotechnology, Science College, University of Anbar, Ramadi, Anbar 46006, Iraq - Published online on: February 21, 2022 https://doi.org/10.3892/mco.2022.2519
- Article Number: 86
-
Copyright: © Shaban et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144:1941–1953. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Parkin DM, Pisani P and Ferlay J: Global Cancer Statistics. CA Cancer J Clin. 49:33–640. 1. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Li Y, Gu M, Jing F, Cai S, Bao C, Wang J, Jin M and Chen K: Association between physical activity and all cancer mortality: Dose-response meta-analysis of cohort studies. Int J Cancer. 138:818–832. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Ye D, Jiang D, Zhang X and Mao Y: Alu methylation and risk of cancer: A meta-analysis. Am J Med Sci. 359:271–280. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Arko-Boham B, Aryee NA, Blay RM, Owusu EDA, Tagoe EA, Doris Shackie ES, Debrah AB and Adu-Aryee NA: Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers. Cancer Genet. 235-236:65–71. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Pan Y, Liu G, Zhou F, Su B and Li Y: DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med. 18:1–14. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Schwarzenbach H, Hoon DS and Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 11:426–437. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Shen J, Stass SA and Jiang F: MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 329:125–136. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Paterlini-Brechot P and Benali NL: Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Lett. 253:180–204. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S, Cuk K, Riethdorf S, Trumpp A, Pantel K, et al: Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat. 146:163–174. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, et al: Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 132:1602–1612. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Cuk K, Zucknick M, Madhavan D, Schott S, Golatta M, Heil J, Marmé F, Turchinovich A, Sinn P, Sohn C, et al: Plasma MicroRNA panel for minimally invasive detection of breast cancer. PLoS One. 8(e76729)2013.PubMed/NCBI View Article : Google Scholar | |
|
Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R, et al: Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res. 18:5972–5982. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Tuchalska-Czuroń J, Lenart J, Augustyniak J and Durlik M: Clinical value of tissue DNA integrity index in pancreatic cancer. Surgeon. 18:269–279. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chudasama DY, Aladag Z, Felicien MI, Hall M, Beeson J, Asadi N, Gidron Y, Karteris E and Anikin VB: Prognostic value of the DNA integrity index in patients with malignant lung tumors. Oncotarget. 9:21281–21288. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Li M, Jia Y, Xu J, Cheng X and Xu C: Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: A single-center experience. Ann Hematol. 96:1343–1351. 2017.PubMed/NCBI View Article : Google Scholar | |
|
El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau F, Theillet C, et al: Circulating DNA as a strong multimarker prognostic tool for metastatic colorectal cancer patient management care. Clin Cancer Res. 22:3067–3077. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Cheng J, Holland-Letz T, Wallwiener M, Surowy H, Cuk K, Schott S, Trumpp A, Pantel K, Sohn C, Schneeweiss A and Burwinkel B: Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer. Breast Cancer Res Treat. 169:69–82. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Habeeb WH, Suleiman AA and Al-Hitawee HT: Exploration of the beta-actin DNA integrity index as early genetic marker of presence of breast cancer. Electron J Gen Med. 17(em188)2020. | |
|
Akca H, Demiray A, Yaren A, Bir F, Koseler A, Iwakawa R, Bagci G and Yokota J: Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer Genet. 206:73–80. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Iqbal S, Vishnubhatla S, Raina V, Sharma S, Gogia A, Deo SS, Mathur S and Shukla NK: Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer. Springerplus. 4(265)2015.PubMed/NCBI View Article : Google Scholar | |
|
Mandel P and Metais P: Nuclear Acids In Human Blood Plasma. C R Seances Soc Biol Fil. 14:241–243. 1948.PubMed/NCBI(In French). | |
|
Tan EM, Schur PH, Carr RI and Kunkel HG: Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest. 45:1732–1740. 1966.PubMed/NCBI View Article : Google Scholar | |
|
Leon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:646–650. 1977.PubMed/NCBI | |
|
Fleischhacker M and Schmidt B: Circulating nucleic acids (CNAs) and cancer-A survey. Biochim Biophys Acta. 1775:181–232. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD and Knippers R: DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61:1659–1665. 2001.PubMed/NCBI | |
|
Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S and Hoon DSB: Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 24:4270–4276. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H, et al: Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 102:16368–16373. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Stamenkovic S, Cheng J, Surowy H, Burwinkel B and Gündert M: Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study. Cancer Biomark. 28:159–167. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Hao TB, Shi W, Shen XJ, Shen XJ, Qi J, Wu XH, Wu Y, Tang YY and Ju SQ: Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 111:1482–1489. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Leng S, Zheng J, Jin Y, Zhang H, Zhu Y, Wu J, Xu Y and Zhang P: Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis. Clin Chim Acta. 477:160–165. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Vizza E, Corrado G, De Angeli M, Carosi M, Mancini E, Baiocco E, Chiofalo B, Patrizi L, Zampa A, Piaggio G and Cicchillitti L: Serum DNA integrity index as a potential molecular biomarker in endometrial cancer. J Exp Clin Cancer Res. 37(16)2018.PubMed/NCBI View Article : Google Scholar | |
|
Thakur S, Tobey A, Daley B, Auh S, Walter M, Patel D, Nilubol N, Kebebew E, Patel A, Jensen K, et al: Limited utility of circulating cell-free dna integrity as a diagnostic tool for differentiating between malignant and benign thyroid nodules with indeterminate cytology (Bethesda Category III). Front Oncol. 9(905)2019.PubMed/NCBI View Article : Google Scholar | |
|
Park MK, Lee JC, Lee JW and Hwang SJ: Alu cell-free DNA concentration, Alu index, and LINE-1 hypomethylation as a cancer predictor. Clin Biochem. 94:67–73. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Salem R, Ahmed R, Shaheen K, Abdalmegeed M and Hassan H: DNA integrity index as a potential molecular biomarker in colorectal cancer. Egypt J Med Hum Genet. 21(38)2020. | |
|
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, et al: Initial sequencing and analysis of the human genome. Nature. 409:860–921. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Cheng J, Tang Q, Cao X and Burwinkel B: Cell-free circulating DNA integrity based on peripheral blood as a biomarker for diagnosis of cancer: A systematic review. Cancer Epidemiol Biomarkers Prev. 26:1595–1602. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ and Hoon DSB: Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: Direct quantitative PCR for ALU repeats. Clin Chem. 52:1062–1069. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, Roden R, Sokoll LJ, Chan DW and Shih IeM: Increased plasma DNA integrity in cancer patients. Cancer Res. 63:3966–3968. 2003.PubMed/NCBI | |
|
Holdenrieder S, Burges A, Reich O, Spelsberg FW and Stieber P: DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann N Y Acad Sci. 1137:162–170. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Boddy JL, Gal S, Malone PR, Shaida N, Wainscoat JS and Harris AL: The role of cell-free DNA size distribution in the management of prostate cancer. Oncol Res. 16:35–41. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Schmidt B, Weickmann S, Witt C and Fleischhacker M: Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann N Y Acad Sci. 1137:207–213. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Agostini M, Enzo MV, Bedin C, Belardinelli V, Goldin E, Del Bianco P, Maschietto E, D'Angelo E, Izzi L, Saccani A, et al: Circulating cell-free DNA: A promising marker of regional lymphonode metastasis in breast cancer patients. Cancer Biomark. 11:89–98. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Lehner J, Stötzer OJ, Fersching D, Nagel D and Holdenrieder S: Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy. Clin Chim Acta. 425:206–211. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Stötzer OJ, Lehner J, Fersching-Gierlich D, Nagel D and Holdenrieder S: Diagnostic relevance of plasma DNA and DNA integrity for breast cancer. Tumor Biol. 35:1183–1191. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Cheng J, Cuk K, Heil J, Golatta M, Schott S, Sohn C, Schneeweiss A, Burwinkel B and Surowy H: Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence. Oncotarget. 8:54537–54547. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Hussein NA, Mohamed SN and Ahmed MA: Plasma ALU-247, ALU-115, and cfDNA integrity as diagnostic and prognostic biomarkers for breast cancer. Appl Biochem Biotechnol. 187:1028–1045. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Feng J, Gang F, Li X, Jin T, Houbao H, Yu C and Guorong L: Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen. Int Urol Nephrol. 45:1023–1028. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Fawzy A, Sweify KM, El-Fayoumy HM and Nofal N: Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence. J Egypt Natl Canc Inst. 28:235–242. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Khani M, Hosseini J, Mirfakhraie R, Habibi M, Azargashb E and Pouresmaeili F: The value of the plasma circulating cell-free DNA concentration and integrity index as a clinical tool for prostate cancer diagnosis: A prospective case-control cohort study in an Iranian population. Cancer Manag Res. 11:4549–4556. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhang R, Pu W, Zhang S, Chen L, Zhu W, Xiao L, Xing C and Li K: Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: A retrospective cohort trial. PLoS One. 13(e0191756)2018.PubMed/NCBI View Article : Google Scholar | |
|
Tanaka H, Tsuda H, Nishimura S, Nomura H, Kataoka F, Chiyoda T, Tanaka K, Iguchi Y, Susumu N and Aoki D: Role of circulating free Alu DNA in endometrial cancer. Int J Gynecol Cancer. 22:82–86. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Waki K, Yokomizo K, Kawano K, Tsuda N, Komatsu N and Yamada A: Integrity of plasma cell-free DNA as a prognostic factor for vaccine therapy in patients with endometrial cancer. Mol Clin Oncol. 14(29)2021.PubMed/NCBI View Article : Google Scholar | |
|
Sikora K, Bedin C, Vicentini C, Malpeli G, D'Angelo E, Sperandio N, Lawlor RT, Bassi C, Tortora G, Nitti D, et al: Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. Int J Biol Markers. 30:e136–e141. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Utomo WK, Janmaat VT, Verhaar AP, Cros J, Lévy P, Ruszniewski P, den Berg MS, Jenster G, Bruno MJ, Braat H, et al: DNA integrity as biomarker in pancreatic cyst fluid. Am J Cancer Res. 6:1837–1841. 2016.PubMed/NCBI | |
|
Mead R, Duku M, Bhandari P and Cree IA: Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer. 105:239–245. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Leszinski G, Lehner J, Gezer U and Holdenrieder S: Increased DNA integrity in colorectal cancer. In Vivo. 28:299–303. 2014.PubMed/NCBI | |
|
El-Gayar D, El-Abd N, Hassan N and Ali R: Increased free circulating DNA integrity index as a serum biomarker in patients with colorectal carcinoma. Asian Pacific J Cancer Prev. 17:939–944. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Bedin C, Enzo MV, Del Bianco P, Pucciarelli S, Nitti D and Agostini M: Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. Int J Cancer. 140:1888–1898. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Zhu F, Ma J, Ru D, Wu N, Zhang Y, Li H, Liu X, Li J, Zhang H, Xu Y, et al: Plasma DNA Integrity as a prognostic biomarker for colorectal cancer chemotherapy. J Oncol. 2021(5569783)2021.PubMed/NCBI View Article : Google Scholar | |
|
Soliman SES, Alhanafy AM, Habib MSE, Hagag M and Ibrahem RAL: Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer. Biochem Biophys Rep. 15:45–51. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Waki K, Yokomizo K, Yoshiyama K, Takamori S, Komatsu N and Yamada A: Integrity of circulating cell-free DNA as a prognostic biomarker for vaccine therapy in patients with nonsmall cell lung cancer. Immunopharmacol Immunotoxicol. 43:176–182. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Ren S, Ren X, Guo H, Liang L, Wei K, Guo L, Qu X, Dai X and Huang Q: Concentration and integrity indexes of urine cell-free DNA as promising biomarkers for early lung cancer diagnosis. Per Med. 18:129–139. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Jiang P, Chan CW, Chan KC, Cheng SH, Wong J, Wong VW, Wong GL, Chan SL, Mok TS, Chan HL, et al: Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci USA. 112:E1317–E1325. 2015.PubMed/NCBI View Article : Google Scholar |
